Drug Trial Radar · NCT04880109
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Last checked: Nov 20, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
16
Actual
Start
Oct 20, 2021
Primary completion
Apr 28, 2022
Study completion Apr 28, 2022
Sponsor
- Lead sponsor
- Aptabio Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Covance
- First posted
- May 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19. It is anticipated that approximately 80 patients will be randomized into the study in a 1:1 ratio to 100 mg APX-115 or placebo arm.
Conditions
- COVID-19
Interventions
APX-115Drug
Oral administration of APX-115 100 mg capsule once daily for 14 days
PlaceboDrug
Oral administration of placebo capsule once daily for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: over the 60-day period
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
FASN, FAHA; John L. McClellan Memorial Veterans Hospital
Little Rock, Arkansas
Anne Arundel Medical Center
Annapolis, Maryland
MSc, FAAN; Metro Health Hospital - Professional Building
Wyoming, Michigan
FCCP; Jamaica Hospital Medical Center
Jamaica, New York
TriHealth Bethesda North Hospital
Cincinnati, Ohio
Medical City Fort Worth
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.